Photo from wikipedia
To Investigate the pharmacokinetic/pharmacodynamic (PK/PD) parameters of high‐dose tigecycline in plasma and sputum of patients with hospital‐acquired pneumonia (HAP), and provide a therapeutic regimen of multidrug‐resistant bacteria (MDRB) infections. Click to show full abstract
To Investigate the pharmacokinetic/pharmacodynamic (PK/PD) parameters of high‐dose tigecycline in plasma and sputum of patients with hospital‐acquired pneumonia (HAP), and provide a therapeutic regimen of multidrug‐resistant bacteria (MDRB) infections.
Keywords:
plasma sputum;
sputum patients;
pharmacokinetic pharmacodynamic;
patients hospital;
dose tigecycline;
high dose
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!